Non-destructive Remote Determination of Total Native Protein Concentration in Virus-Like Particle Vaccine Preparations
Abstract
Introduction. Virus-Like Particles (VLPs) are nanoscale entities characterized by surface shape heterogeneity and enhanced emission activity in the millimeter wavelength range (30-300 GHz), which is influenced by external physical factors such as heating or electromagnetic radiation. This phenomenon presents opportunities for the noninvasive determination of accurate concentrations of the protein component in commercially prepared VLP vaccines.
Objective. To propose a modern and rapid approach for the quantitative determination of native proteins in VLP-containing vaccines, which enables research to be conducted without opening the primary packaging.
Materials and methods. Vaccines imitating rotavirus (Gam-VLP-Rota) and SARS-CoV2 virus (Gam-VLP-multivac) were studied. The density of the radiothermal emission flux at extremely high frequency (EHF) wavelengths was measured using a TES-92 device. The reference values for protein concentration in vaccines, prior to the addition of the adjuvant, were measured using the commercial "Micro BCA™ Protein Assay Kit". The dimensional characteristics of the VLP vaccine were analyzed using dynamic laser light scattering (Zetasizer Nano ZSP).
Results. A strong linear correlation (r = 0.99) was established between the flux density of radiothermal emission and the protein content in vaccines, allowing for analysis without opening the packaging. The validation procedure for this technique assessed linearity, accuracy, and intra-laboratory precision for Gam-VLP-multivac.
Conclusion. The values of the intrinsic radiothermal emission flux density enabled the determination of the native concentration of complex-shaped virus-like nanoparticles in vaccines without the need to open the primary packaging, irrespective of the presence of an adjuvant.
Keywords: VLP, Virus-Like Particles, quality control, protein concentration determination, radiothermal emission.
Keywords:
VLP, Virus-Like Particles, quality control , protein concentration determination, , radiothermal emissionDOI
https://doi.org/10.22270/jddt.v15i8.7320References
1. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320-32. https://doi.org/10.1056/NEJMoa2026920
2. Mohsen MO, Augusto G, Bachmann MF. The 3Ds in virus-like particle based-vaccines: design, delivery and dynamics. Immunol Rev. 2020;296:155-68. https://doi.org/10.1111/imr.12863
3. Chernoryzh YaYu, Kondratieva VM, Malkova AP, Savochkina TE, Eliseeva OV, Latyshev OE, et al. Pre-clinical safety studies of intranasal virus-like particle based vaccine for COVID-19 prevention. Probl Virol. 2025;70(1):35-46. https://doi.org/10.36233/0507-4088-278
4. Filatov IE, Silaenkova MM, Tsibezov VV, Balandina MV, Norkina SN, Latyshev OE, et al. Enzyme-linked immunosorbent assay to determine the potency of a rotavirus vaccine based on virus-like particles: analytical procedure development and validation. Biol Prod Prev Diagn Treat. 2024;24(4):389-402. https://doi.org/10.30895/2221-996X-2024-24-4-389-402
5. Mohsen M, Gomes A, Vogel M, Bachmann M. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. Vaccines (Basel). 2018;6(3):37. https://doi.org/10.3390/vaccines6030037
6. Latyshev OE, Zaykova ON, Eliseeva OV, Savochkina TE, Chernoryzh YaYu, Syroeshkin AV, et al. Development, production and characterization of SARS-CoV-2 virus-like particles (Coronaviridae: Orthocoronavirinae: Betacoronavirus: Sarbecovirus). Probl Virol. 2024;69(2):175-86. https://doi.org/10.36233/0507-4088-226
7. Shoja Z, Jalilvand S, Latifi T, Roohvand F. Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials. Arch Virol. 2022;167(4):1013-23. https://doi.org/10.1007/s00705-022-05407-9
8. United States Pharmacopeia–National Formulary. <507> PROTEIN DETERMINATION PROCEDURES. USP-NF 2023. Available from: https://online.uspnf.com/uspnf. Accessed 25 May 2025.
9. European Pharmacopoeia. 2.5.33. Total Protein. 11.2 ed. Strasbourg: Council of Europe; 2024. Available from: https://pheur.edqm.eu/subhome/11-2. Accessed 25 Nov 2024.
10. Syroeshkin AV, Petrov GV, Taranov VV, Pleteneva TV, Koldina AM, Gaydashev IA, et al. Radiothermal emission of nanoparticles with a complex shape as a tool for the quality control of pharmaceuticals containing biologically active nanoparticles. Pharmaceutics. 2023;15:966. https://doi.org/10.3390/pharmaceutics15030966
11. Latyshev OE, Zaykova ON, Eliseeva OV, Savochkina TE, Chernoryzh YaYu, Syroeshkin AV, et al. Probl Virol. 2024;69(2):175-86. https://doi.org/10.36233/0507-4088-226
12. Nazarov AA, Ledenev OV, Petrov GV, Levitskaya OV, Syroeshkin AV. New method of quality and quantity control of the insulin glulisine pharmaceuticals based on intrinsic radiothermal emission. J Drug Deliv Ther. 2025;15(6):116-25. http://dx.doi.org/10.22270/jddt.v15i6.7189
13. Pogarskaya AS, Konfino KV. The implementation of cold chain approach at transportation and storage of immunobiological preparations. Probl Soc Gig Zdravookhr Istor Med. 2022;30(4):666-72. https://doi.org/10.32687/0869-866X-2022-30-4-666-672 (in Russian).
14. Firdaus FZ, Skwarczynski M, Toth I. Developments in vaccine adjuvants. Methods Mol Biol. 2022;2412:145-78. https://doi.org/10.1007/978-1-0716-1892-9_8
15. Petrov GV, Galkina DA, Koldina AM, Lebedeva VV, Syroeshkin AV. Controlling the quality of nanodrugs according to their new property—radiothermal emission. Pharmaceutics. 2024;16(2):180. https://doi.org/10.3390/pharmaceutics16020180
16. Kaczmarczyk LS, Marsay KS, Shevchenko S, Pilossof M, Levi N, Einat M, et al. Corona and polio viruses are sensitive to short pulses of W-band gyrotron radiation. Environ Chem Lett. 2021;19(6):3967-72. https://doi.org/10.1007/s10311-021-01300-0
Published
Abstract Display: 266 
PDF Downloads: 345 PDF Downloads: 16 How to Cite
Issue
Section
Copyright (c) 2025 Olga V. Levitskaya , Gleb V. Petrov , Oleg V. Ledenev , Dmitriy Yu. Yakunin , Tatyana V. Grebennikova
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.